Cancer Expert MD

Few moments in cancer are harder than hearing that chemotherapy has stopped working. The scans show growth, a tumor marker is rising, and the treatment that once helped no longer does. For people with Stage IV cancer, this moment often comes more than once. But it is not the end of options. It is a turning point that calls for new information about the cancer as it is now, not as it was at diagnosis. This article explains why chemotherapy stops working and the steps that can open the next door.

Why Chemotherapy Stops Working

Survival of the toughest cells. A tumor is not one uniform mass. It contains many slightly different groups of cells. Chemotherapy kills the sensitive ones, and the few that happen to resist survive and regrow. The cancer that returns is often a different cancer, genetically, from the one first treated.

Drug pumps. Cancer cells can switch on pumps in their outer membrane, such as P-glycoprotein, that push chemotherapy drugs out before they can work.

Stronger DNA repair. Many chemotherapy drugs work by damaging DNA. Resistant cells repair that damage faster.

Cancer stem cells and dormant cells. Slow-dividing stem-like cells escape drugs that target rapidly dividing cells, and can rebuild the tumor. Our article on why cancer comes back explains these cells in detail.

The environment around the tumor. Poor blood flow, low oxygen, scar-like tissue and immune-suppressing cells around a tumor can shield it from drugs.

Step 1: Confirm That It Has Truly Stopped Working

One rising tumor marker is not proof. Markers fluctuate, and a single value can mislead. A trend across several measurements, read together with imaging, is more reliable. With immunotherapy, tumors can briefly appear larger before shrinking, a phenomenon called pseudoprogression, as immune cells flood into them. Before abandoning a treatment, make sure the evidence is consistent.

Step 2: Re-Test the Cancer as It Is Now

Because resistant cancer is often genetically different, the original biopsy may no longer describe it. Re-testing can reveal new targets.

Liquid biopsy. A ctDNA blood test can detect new resistance mutations without another biopsy. In hormone receptor-positive breast cancer, for example, the SERENA-6 trial showed that switching treatment as soon as a resistance mutation called ESR1 appeared in the blood extended the time the cancer stayed controlled.

Comprehensive sequencing. If earlier testing was a small panel or DNA only, broader testing that includes RNA may find targets that were missed, such as gene fusions with highly effective targeted drugs. See our article on tumor DNA and RNA sequencing.

Circulating tumor cells. Circulating tumor cell testing can reveal targets that the original biopsy did not show. In the German DETECT III trial, women with HER2-negative breast cancer whose circulating cells carried HER2 lived longer when a HER2-targeted drug was added.

Step 3: Have the Results Reviewed by a Molecular Tumor Board

A molecular tumor board is a panel of oncologists, pathologists, geneticists and scientists who review a patient’s full molecular profile and recommend a matched treatment. Germany has made them a routine part of cancer care at its university centers.

The evidence is growing. A 2025 systematic review and meta-analysis of molecular tumor board studies, most of them from Germany, found that patients who received the recommended therapies, nearly all of whom had already exhausted standard treatment, had a median overall survival of 13.5 months.¹ In a 2026 study of patients with advanced melanoma at two German university centers, Freiburg and Hamburg, those who received the board’s recommended therapy had longer progression-free survival (7.9 versus 4.3 months) and overall survival (10.6 versus 5.1 months) than those who did not, although the authors caution that patients who did not receive the recommendation were often sicker.² The strongest evidence comes from Italy: in the randomized ROME trial, pretreated patients with metastatic cancer whose therapy was guided by comprehensive genomic profiling and a molecular tumor board had higher response rates and longer progression-free survival than those given standard treatment.³ In 2025, Germany’s national cancer research center launched its own randomized trial, RATIONALE, to test this approach in rare cancers.³

Step 4: Test What Actually Kills Your Cancer

Sequencing shows what a cancer is built from. Chemosensitivity testing shows what happens when drugs meet the cancer’s own living cells. After resistance has developed, testing fresh tumor cells, organoids or circulating tumor cells against the remaining options can help avoid drugs the cancer already resists. Laboratories in Germany and Greece also test cancer cells against repurposed drugs and natural compounds. See cancer testing in Germany and Greece.

Step 5: Change the Strategy, Not Just the Drug

Targeted therapy and immunotherapy. New test results may point to a targeted drug, or to immunotherapy when the cancer carries many mutations or a mismatch repair defect.

A different schedule. Metronomic chemotherapy, given at low doses continuously, attacks the tumor’s blood supply and immune defenses rather than only the cancer cells, and in a randomized trial in recurrent head and neck cancer it outlived standard intravenous cisplatin.

Heat. Hyperthermia disables the DNA repair that resistant cells depend on and increases drug uptake. Randomized trials in Germany and the Netherlands showed that adding heat to chemotherapy or radiation improved survival in sarcoma and cervical cancer.

Repurposed drugs that act on resistance. In laboratory studies, several repurposed drugs act on the mechanisms behind resistance: metformin targets cancer stem cells, and ivermectin blocks the P-glycoprotein drug pump. These are laboratory findings that have not yet been proven to reverse resistance in patients. See our guide to repurposed drugs for cancer.

Step 6: Look at Clinical Trials, Including Abroad

Clinical trials offer access to treatments not yet approved, including new targeted drugs, antibody-drug conjugates, cell therapies and cancer vaccines. Many trials are designed specifically for patients whose cancer has progressed on standard treatment. They can be searched at ClinicalTrials.gov and, for trials in Europe, the EU Clinical Trials Register. A molecular profile makes the search far more productive, because many trials now enroll patients by mutation rather than by cancer type.

Step 7: Strengthen the Terrain

Whatever comes next works better in a body that is well nourished, physically active, sleeping well and not inflamed. Unintended weight and muscle loss in particular should be addressed early, because it weakens tolerance of every treatment. Metabolic approaches, discussed in our articles on the Warburg effect and the ketogenic diet, are used alongside treatment, never instead of it.

How Cancer Expert MD Helps

Cancer Expert MD specializes in education and consultation for people with Stage IV and metastatic cancer. When chemotherapy stops working, a consultation reviews the records and test results, identifies the testing that could reveal new options, explains the treatments and trials available in the United States and abroad, and helps patients and families ask better questions of their treating team. Our book, The New Reality of Cancer, covers resistance, re-testing and the full range of next-step strategies in detail.

Frequently Asked Questions

What does it mean when chemotherapy stops working?

It means the cancer has developed resistance: the cells that survived treatment are growing despite the drug. It usually shows as growth on scans or a steadily rising tumor marker.

Can a different chemotherapy still work?

Often, yes. Resistance to one drug does not mean resistance to all. Re-testing the cancer and functional testing can help identify which options remain active.

What tests should be done when chemotherapy stops working?

Commonly a ctDNA liquid biopsy or new tissue biopsy with comprehensive DNA and RNA sequencing, and in some cases circulating tumor cell testing or chemosensitivity testing of the cancer’s own cells.

What is a molecular tumor board?

A panel of cancer specialists and scientists who review a patient’s molecular test results and recommend a matched treatment. In a randomized trial in Italy, this approach improved response rates and progression-free survival in pretreated metastatic cancer.

---

More articles on advanced cancer testing, recurrence and survivorship and all articles.

References

1. Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. Published April 2025. PMC11965449.
2. Geidel G, et al. Molecular tumor boards in malignant melanoma: uncovering challenges and opportunities in a bicenter retrospective analysis in Germany. International Journal of Cancer. 2026.
3. ROME trial (Italy), randomized phase II study of genomically guided therapy versus standard of care in pretreated metastatic cancer; and the German Cancer Research Center RATIONALE trial. ClinicalTrials.gov NCT06855134.

This article is for education only. It is not medical advice and does not diagnose or treat any condition. Cancer Expert MD has no financial relationship with any laboratory, drug maker, supplement company, clinic or hospital.